Stock CLARI CLARIANE SE
Add to a list
To use this feature you must be a member
Log inSign up

Financials Clariane SE

Equities

CLARI

FR0010386334

Healthcare Facilities & Services

Market Closed - Euronext Paris
Other stock markets
 11:36:57 2024-04-26 am EDT 		5-day change 1st Jan Change
1.88 EUR +18.69% Intraday chart for Clariane SE +18.54% -21.80%
Apr. 26 CLARIANE : Reiterated outlook backed by a buoyant Q1 Alphavalue
Apr. 26 Transcript : Clariane SE, Q1 2024 Sales/ Trading Statement Call, Apr 26, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,467 3,291 2,938 1,068 256.7 200.7 - -
Enterprise Value (EV) 1 9,630 9,841 9,950 8,605 256.7 5,971 4,857 3,001
P/E ratio 32.5 x 104 x 38.1 x 77.8 x -2.43 x 12.5 x 3.92 x 9.89 x
Yield 1.43% 0.96% 1.08% 2.47% - 18.1% 21.8% 10.6%
Capitalization / Revenue 0.96 x 0.85 x 0.68 x 0.24 x 0.05 x 0.04 x 0.04 x 0.03 x
EV / Revenue 2.67 x 2.54 x 2.31 x 1.9 x 0.05 x 1.13 x 0.87 x 0.51 x
EV / EBITDA 10.9 x 11.4 x 9.85 x 8.58 x 0.25 x 5.82 x 4.36 x 2.57 x
EV / FCF 22,631 x 35.8 x 31.6 x 35.9 x - 8.01 x 8.85 x 4.09 x
FCF Yield 0% 2.79% 3.17% 2.78% - 12.5% 11.3% 24.4%
Price to Book 1.35 x 0.91 x 0.84 x 0.3 x - 0.06 x 0.06 x 0.06 x
Nbr of stocks (in thousands) 82,701 105,016 105,546 105,546 106,781 106,781 - -
Reference price 2 41.92 31.34 27.84 10.12 2.404 1.880 1.880 1.880
Announcement Date 2/27/20 2/24/21 2/23/22 2/21/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,612 3,874 4,311 4,534 5,048 5,293 5,579 5,886
EBITDA 1 884.9 861.1 1,010 1,003 1,021 1,026 1,115 1,168
EBIT 1 374.3 304.4 341.9 348.3 328.1 326.7 373.9 397
Operating Margin 10.36% 7.86% 7.93% 7.68% 6.5% 6.17% 6.7% 6.74%
Earnings before Tax (EBT) 1 175.5 60 131.9 57.9 -76.2 -37 56 51
Net income 1 114.7 39.4 94.6 22.1 -105.2 -21.77 58 23.7
Net margin 3.18% 1.02% 2.19% 0.49% -2.08% -0.41% 1.04% 0.4%
EPS 2 1.290 0.3000 0.7300 0.1300 -0.9900 0.1500 0.4800 0.1900
Free Cash Flow 1 0.4255 274.8 315.2 239.5 - 745 548.6 732.8
FCF margin 0.01% 7.09% 7.31% 5.28% - 14.08% 9.83% 12.45%
FCF Conversion (EBITDA) 0.05% 31.92% 31.22% 23.87% - 72.61% 49.2% 62.77%
FCF Conversion (Net income) 0.37% 697.52% 333.24% 1,083.71% - - 945.86% 3,091.98%
Dividend per Share 2 0.6000 0.3000 0.3000 0.2500 - 0.3400 0.4100 0.2000
Announcement Date 2/27/20 2/24/21 2/23/22 2/21/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1
Net sales 1 1,845 1,876 2,108 1,082 1,121 - 1,094 1,130 2,224 1,135 1,190 - 1,267 2,485 1,246 1,316 - 1,308
EBITDA - 407.3 - - - - - - 491.1 - - - - 482 - - - -
EBIT 211.6 141 166.2 - - 175.7 - - 168.9 - - 179.4 - 144.5 - - 183.6 -
Operating Margin 11.47% 7.51% 7.89% - - - - - 7.59% - - - - 5.82% - - - -
Earnings before Tax (EBT) - - - - - - - - - - - - - - - - - -
Net income 54.6 - - - - - - - - - - - - - - - - -
Net margin 2.96% - - - - - - - - - - - - - - - - -
EPS - - - - - - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - - - - -
Announcement Date 2/27/20 7/30/20 7/29/21 10/28/21 2/23/22 2/23/22 4/25/22 7/28/22 7/28/22 10/27/22 2/21/23 2/21/23 7/27/23 7/27/23 10/24/23 2/28/24 2/28/24 -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 6,163 6,550 7,012 7,537 - 5,770 4,656 2,800
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 6.965 x 7.607 x 6.944 x 7.513 x - 5.624 x 4.176 x 2.398 x
Free Cash Flow 1 0.43 275 315 240 - 745 549 733
ROE (net income / shareholders' equity) 4.48% 1.38% 2.84% 0.63% - 0.28% 1.7% 1.25%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 31.10 34.30 33.20 33.80 - 33.40 33.50 33.30
Cash Flow per Share 2 8.280 7.510 6.990 7.150 - 7.280 7.770 1.410
Capex 1 311 520 539 622 - 467 480 330
Capex / Sales 8.6% 13.43% 12.49% 13.72% - 8.81% 8.61% 5.6%
Announcement Date 2/27/20 2/24/21 2/23/22 2/21/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Clariane SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
1.88 EUR
Average target price
3.825 EUR
Spread / Average Target
+103.46%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
CLARIANE SE Stock Clariane SE
-21.80% 214M
CVS HEALTH CORPORATION Stock CVS Health Corporation
-14.92% 84.68B
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+13.30% 81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+10.92% 29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-12.71% 16.73B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-3.06% 16.36B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-2.63% 14.92B
PURE HEALTH HOLDING Stock Pure Health Holding
-31.75% 11.77B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
-1.42% 11.72B
DAVITA INC. Stock DaVita Inc.
+27.44% 11.71B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. CLARI Stock
  4. Financials Clariane SE